MAESTrO: Antihaemophilic factor (recombinant BDD) Fc fusion protein (Eloctate): treatment cost comparison and budget impact analysis

Posted by Michael Wonder on 12 Nov 2015

Antihaemophilic factor (recombinant BDD) Fc fusion protein (Eloctate): treatment cost comparison and budget impact analysis

9 November 2015 - CADTH's final science report is now available for the project on antihaemophilic factor (recombinant BDD) Fc fusion protein (Eloctate): treatment cost comparison and budget impact analysis.

For more details, go to: https://www.cadth.ca/antihemophilic-factor-recombinant-bdd-fc-fusion-protein-eloctate-treatment-cost-comparison-and

Posted by:

Michael Wonder

Posted in:

Health technology assessment , Canada , Blood product , Budget impact analysis